KR100818904B1 - 서방형 미세결정성 펩타이드 현탁액 - Google Patents

서방형 미세결정성 펩타이드 현탁액 Download PDF

Info

Publication number
KR100818904B1
KR100818904B1 KR1020047003371A KR20047003371A KR100818904B1 KR 100818904 B1 KR100818904 B1 KR 100818904B1 KR 1020047003371 A KR1020047003371 A KR 1020047003371A KR 20047003371 A KR20047003371 A KR 20047003371A KR 100818904 B1 KR100818904 B1 KR 100818904B1
Authority
KR
South Korea
Prior art keywords
suspension
delete delete
aqueous suspension
teverelix
teberelix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020047003371A
Other languages
English (en)
Korean (ko)
Other versions
KR20040037077A (ko
Inventor
데젠지로마노
부띠뇽프랑수와
Original Assignee
아다나 바이오싸이언스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아다나 바이오싸이언스 리미티드 filed Critical 아다나 바이오싸이언스 리미티드
Publication of KR20040037077A publication Critical patent/KR20040037077A/ko
Application granted granted Critical
Publication of KR100818904B1 publication Critical patent/KR100818904B1/ko
Assigned to 메디칼 리서치 카운실 테크놀로지 reassignment 메디칼 리서치 카운실 테크놀로지 권리의 전부이전등록 Assignors: 아다나 바이오싸이언스 리미티드
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020047003371A 2001-09-06 2002-08-27 서방형 미세결정성 펩타이드 현탁액 Expired - Lifetime KR100818904B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31761601P 2001-09-06 2001-09-06
US60/317,616 2001-09-06
PCT/EP2002/009537 WO2003022243A2 (en) 2001-09-06 2002-08-27 Sustained release of microcrystalline peptide suspensions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020077021972A Division KR20070107161A (ko) 2001-09-06 2002-08-27 서방형 미세결정성 펩타이드 현탁액

Publications (2)

Publication Number Publication Date
KR20040037077A KR20040037077A (ko) 2004-05-04
KR100818904B1 true KR100818904B1 (ko) 2008-04-04

Family

ID=23234486

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020047003371A Expired - Lifetime KR100818904B1 (ko) 2001-09-06 2002-08-27 서방형 미세결정성 펩타이드 현탁액
KR1020077021972A Ceased KR20070107161A (ko) 2001-09-06 2002-08-27 서방형 미세결정성 펩타이드 현탁액

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020077021972A Ceased KR20070107161A (ko) 2001-09-06 2002-08-27 서방형 미세결정성 펩타이드 현탁액

Country Status (26)

Country Link
US (5) US7098305B2 (https=)
EP (2) EP1423150B1 (https=)
JP (3) JP2005504787A (https=)
KR (2) KR100818904B1 (https=)
CN (1) CN100386116C (https=)
AR (1) AR042592A1 (https=)
AT (1) ATE463258T1 (https=)
AU (1) AU2002337025B2 (https=)
BR (1) BR0212333A (https=)
CA (1) CA2459309C (https=)
CY (1) CY1118642T1 (https=)
DE (1) DE60235896D1 (https=)
DK (1) DK2198888T3 (https=)
ES (2) ES2362505T3 (https=)
HU (1) HUP0402099A2 (https=)
IL (1) IL160443A0 (https=)
MX (1) MXPA04002185A (https=)
NO (1) NO20040938L (https=)
NZ (1) NZ531734A (https=)
PL (1) PL368056A1 (https=)
PT (1) PT2198888T (https=)
RU (1) RU2311195C2 (https=)
TW (1) TWI249409B (https=)
UA (1) UA79435C2 (https=)
WO (1) WO2003022243A2 (https=)
ZA (1) ZA200401390B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
GB0511269D0 (en) * 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
WO2008071984A1 (en) * 2006-12-13 2008-06-19 Ardana Bioscience Limited Administration of the gonadotropin-releasing hormone antagonist teverelix
PE20090943A1 (es) 2007-07-16 2009-08-05 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
EP2176295B1 (en) 2007-07-16 2014-11-19 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
KR101607346B1 (ko) 2008-01-31 2016-03-29 제넨테크, 인크. 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
RU2517135C2 (ru) * 2008-05-07 2014-05-27 Меррион Рисерч Iii Лимитед Композиции пептидов и способы их получения
CA2751854A1 (en) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition and drug delivery of bisphosphonates
MX2011011431A (es) * 2009-05-01 2012-02-23 Ferring Bv Composicion para el tratamiento de cancer de prostata.
PT2523653T (pt) 2010-01-13 2018-06-28 Ipsen Pharma Sas Processo para a preparação de composições farmacêuticas para a libertação prolongada de análogos de somatostatina
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
US8927687B2 (en) 2010-07-09 2015-01-06 Amylin Pharmaceuticals, Llc Microcrystalline Y receptor agonists
KR20140026354A (ko) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
EP2823808A1 (en) 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
EP2832361A1 (en) * 2013-07-29 2015-02-04 Ipsen Pharma S.A.S. Aqueous sustained release compositions of LHRH analogs
CN104844694A (zh) * 2014-02-17 2015-08-19 深圳翰宇药业股份有限公司 一种醋酸加尼瑞克的制备方法
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
HUE049175T2 (hu) 2014-09-23 2020-09-28 Hoffmann La Roche Eljárás anti-CD79b immunkonjugátumok alkalmazására
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
CA2989269C (en) 2015-06-15 2020-09-22 Robert Yongxin Zhao Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR20220150408A (ko) 2016-11-14 2022-11-10 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
BR112019014192A2 (pt) * 2017-01-30 2020-02-11 Antev Limited Composição compreendendo pelo menos um antagonista de gnrh
RU2019144532A (ru) 2017-06-30 2021-07-30 Антев Лимитед Композиция для лечения острой задержки мочи
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
EP3802562A4 (en) * 2018-05-28 2022-06-01 Jiangyin Usun Pharmaceutical Co., Ltd. New pharmaceutical use
EP3590524B1 (en) * 2018-07-05 2020-11-04 Antev Limited A method of reconstituting a teverelix-tfa composition
EP3590526A1 (en) 2018-07-05 2020-01-08 Antev Limited A lyophilization process and a teverelix-tfa lyophilizate obtained thereby
EP3590525A1 (en) * 2018-07-05 2020-01-08 Antev Limited Teverelix-tfa composition
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773032A (en) * 1993-12-09 1998-06-30 Asta Medica Aktiengellschaft Long-acting injection suspensions and a process for their preparation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2668866A (en) * 1951-08-14 1954-02-09 Shell Dev Isomerization of paraffin wax
GB1245187A (en) 1969-02-14 1971-09-08 Continental Can Co Hot melt adhesive composition
JPS5242506A (en) 1975-10-02 1977-04-02 Toa Nenryo Kogyo Kk Hydrotreating process of petroleum wax
JPS5335705A (en) * 1976-09-14 1978-04-03 Toa Nenryo Kogyo Kk Hydrogenation and purification of petroleum wax
US4186078A (en) * 1977-09-12 1980-01-29 Toa Nenryo Kogyo Kabushiki Kaisha Catalyst and process for hydrofining petroleum wax
US4239546A (en) * 1978-07-21 1980-12-16 Petrolite Corporation Hydrocarbon polymers to improve the hardness of waxes
US4256737A (en) * 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US4266737A (en) * 1979-11-05 1981-05-12 Arrow Converting Equipment, Inc. Air differential mandrel and method of differentially winding and rewinding tapes
US4415649A (en) * 1981-02-25 1983-11-15 E. I. Du Pont De Nemours & Co. Flexographic printing plates containing blended adhesives
US4839422A (en) * 1987-12-23 1989-06-13 Exxon Chemical Patents Inc. Ternary adhesive compositions
US5110904A (en) * 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
DE68928278T2 (de) 1988-02-10 1998-03-12 Tap Pharmaceuticals Inc Lhrh-analog
JP2672677B2 (ja) 1989-02-09 1997-11-05 タツプ・フアーマシユーテイカルズ・インコーポレイテツド Ｌｈｒｈ同族体
DE69214818T2 (de) * 1991-04-25 1997-02-27 Romano S.-Cergue Deghenghi LHRH-Antagonisten
EP0625069B1 (de) * 1992-10-26 1998-12-30 Schwarz Pharma Ag Verfahren zur herstellung von mikrokapseln
JPH08504209A (ja) 1992-12-04 1996-05-07 アボツト・ラボラトリーズ ６位修飾デカペプチドｌｈｒｈ拮抗薬
CA2136079A1 (en) 1992-12-18 1994-07-07 Fortuna Haviv Lhrh antagonists having modified aminoacyl residues at positions 5 and 6
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
JP3101695B2 (ja) 1996-07-24 2000-10-23 日本航空電子工業株式会社 軟ｘ線光学素子用多層膜
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
DE19813849A1 (de) * 1998-03-27 1999-09-30 Degussa Verfahren zur einstufigen Umsalzung und Aufreinigung von Oligopeptiden
CO5160256A1 (es) 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
DE10040700A1 (de) * 2000-08-17 2002-02-28 Asta Medica Ag Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
JP4505750B2 (ja) 2006-01-27 2010-07-21 東海ゴム工業株式会社 制振装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773032A (en) * 1993-12-09 1998-06-30 Asta Medica Aktiengellschaft Long-acting injection suspensions and a process for their preparation

Also Published As

Publication number Publication date
DK2198888T3 (en) 2017-02-13
ES2362505T3 (es) 2011-07-06
HUP0402099A2 (hu) 2005-02-28
PT2198888T (pt) 2017-02-10
TWI249409B (en) 2006-02-21
CN100386116C (zh) 2008-05-07
DE60235896D1 (de) 2010-05-20
JP2005504787A (ja) 2005-02-17
UA79435C2 (en) 2007-06-25
JP2013177449A (ja) 2013-09-09
HK1062148A1 (en) 2004-10-21
US20060229238A1 (en) 2006-10-12
WO2003022243A2 (en) 2003-03-20
EP1423150A2 (en) 2004-06-02
ZA200401390B (en) 2004-08-27
US20100239683A1 (en) 2010-09-23
PL368056A1 (en) 2005-03-21
US20060228385A1 (en) 2006-10-12
NZ531734A (en) 2006-02-24
CA2459309C (en) 2012-04-03
US7098305B2 (en) 2006-08-29
RU2311195C2 (ru) 2007-11-27
BR0212333A (pt) 2004-09-21
EP2198888A2 (en) 2010-06-23
AU2002337025B2 (en) 2006-12-07
KR20070107161A (ko) 2007-11-06
CN1551785A (zh) 2004-12-01
AR042592A1 (es) 2005-06-29
ATE463258T1 (de) 2010-04-15
EP2198888A3 (en) 2011-08-31
US8415300B2 (en) 2013-04-09
JP2010095533A (ja) 2010-04-30
NO20040938D0 (no) 2004-03-04
US20030044463A1 (en) 2003-03-06
CA2459309A1 (en) 2003-03-20
JP5757686B2 (ja) 2015-07-29
MXPA04002185A (es) 2004-07-23
US20110312889A1 (en) 2011-12-22
WO2003022243A3 (en) 2003-10-30
EP1423150B1 (en) 2010-04-07
IL160443A0 (en) 2004-07-25
EP2198888B1 (en) 2016-11-02
RU2004110615A (ru) 2005-05-10
CY1118642T1 (el) 2017-07-12
NO20040938L (no) 2004-06-04
ES2618777T3 (es) 2017-06-22
KR20040037077A (ko) 2004-05-04

Similar Documents

Publication Publication Date Title
KR100818904B1 (ko) 서방형 미세결정성 펩타이드 현탁액
AU2002337025A1 (en) Sustained release of microcrystalline peptide suspensions
EP0909175B1 (en) Non-aqueous protic peptide formulations
US5916582A (en) Aqueous formulations of peptides
HK1143313B (en) Sustained release of microcrystalline peptide suspensions
HK1143313A (en) Sustained release of microcrystalline peptide suspensions
HK1062148B (en) Sustained release of microcrystalline peptide suspensions
KR100517091B1 (ko) 펩티드의수성제제
AU5770501A (en) Aqueous formulations of peptides

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040305

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20040604

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20051031

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20061026

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20070620

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20061026

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
AMND Amendment
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20070921

PJ0201 Trial against decision of rejection

Patent event date: 20070921

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20070620

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20080111

Appeal identifier: 2007101010067

Request date: 20070921

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20071022

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20070921

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20070921

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20070226

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20051031

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071105

Patent event code: PE09021S01D

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20080111

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20071029

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20080327

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20080328

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20110217

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20110217

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20120305

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20120305

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20130204

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20130204

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20131115

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20131115

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20160324

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20160324

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20170328

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20170328

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20180313

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20180313

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20190222

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20190222

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20200219

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20200219

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20230227

Termination category: Expiration of duration